Tandem Diabetes Care Inc (NASDAQ:TNDM) CEO John F. Sheridan sold 9,538 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $70.03, for a total value of $667,946.14. Following the transaction, the chief executive officer now owns 12,039 shares in the company, valued at approximately $843,091.17. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
TNDM traded down $6.43 on Monday, hitting $62.14. 120,304 shares of the stock were exchanged, compared to its average volume of 1,250,314. Tandem Diabetes Care Inc has a 12 month low of $26.40 and a 12 month high of $74.81. The business has a 50-day moving average of $64.90 and a two-hundred day moving average of $64.41. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.53 and a quick ratio of 2.21. The firm has a market capitalization of $4.10 billion, a price-to-earnings ratio of -24.37 and a beta of 0.25.
Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, August 1st. The medical device company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.20. Tandem Diabetes Care had a negative net margin of 19.55% and a negative return on equity of 19.31%. The firm had revenue of $93.26 million for the quarter, compared to analyst estimates of $69.95 million. During the same period last year, the firm earned ($0.33) EPS. The business’s quarterly revenue was up 173.2% compared to the same quarter last year. Equities research analysts expect that Tandem Diabetes Care Inc will post -0.65 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC increased its stake in Tandem Diabetes Care by 53.3% in the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 160 shares during the last quarter. Bremer Bank National Association acquired a new position in Tandem Diabetes Care during the first quarter valued at approximately $31,000. TRUE Private Wealth Advisors bought a new stake in Tandem Diabetes Care during the second quarter worth $33,000. James Investment Research Inc. lifted its stake in Tandem Diabetes Care by 15.9% during the second quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock worth $85,000 after purchasing an additional 180 shares during the last quarter. Finally, Stephens Inc. AR acquired a new stake in shares of Tandem Diabetes Care in the 2nd quarter valued at $113,000. 79.50% of the stock is owned by institutional investors.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Further Reading: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.